We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exelixis, Ipsen Report Positive Results on Lead Cancer Drug
Read MoreHide Full Article
Exelixis, Inc. (EXEL - Free Report) and Ipsen announced positive detailed results from the pivotal phase III CELESTIAL study of Cabometyx (cabozantinib) demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma (HCC).
CELESTIAL study met its primary endpoint and cabozantinib provided a statistically significant and clinically meaningful improvement versus placebo in overall survival (OS). The median OS was 10.2 months with Cabometyx compared with 8.0 months with placebo. The Median progression-free survival (PFS) more than doubled, at 5.2 months with Cabometyx compared with 1.9 months with placebo. The trial showed that disease control (partial response or stable disease) was achieved by 64% of the Cabometyx group compared with 33% of the placebo group. The companies plan to present the results at a symposium in San Francisco later this week.
We remind investors that Cabometyx is already approved in the United States for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. In December 2017, the FDA approved label expansion of Cabometyx for the treatment of previously untreated RCC. The approval came on the back of positive results from the randomized phase II, trial CABOSUN on first-line kidney cancer. The results demonstrated statistically significant and clinically meaningful improvement in PFS versus Pfizer Inc.’s (PFE - Free Report) Sutent.
Exelixis’ share price has increased 64.5% over a year compared with the industry’s gain of 2.6%.
HCC is the most common form of liver cancer, accounting for more than 90% of cases in the United States. Hence there is a dire need to bring new treatment options. Exelixis plans to submit a supplemental new drug application to the FDA in the first quarter of 2018.
Cabometyx raked in strong sales in the first nine months of 2017, courtesy of the increasing demand for the drug. A potential approval will further boost the sales of the drug. .
Exelixis has also initiated a phase Ib study (investigator-sponsored) on Cabometyx (in combination with Bristol-Myers Squibb Company’s (BMY - Free Report) Opdivo (nivolumab) or Opdivo plus Yervoy) in patients suffering from genitourinary tumors, including bladder cancer and RCC.
Exelixis has also inked agreements with Bristol-Myers Squibb and Roche Holding AG (RHHBY - Free Report) to develop cabozantinib in combination with immunotherapy agents.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Exelixis, Ipsen Report Positive Results on Lead Cancer Drug
Exelixis, Inc. (EXEL - Free Report) and Ipsen announced positive detailed results from the pivotal phase III CELESTIAL study of Cabometyx (cabozantinib) demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma (HCC).
CELESTIAL study met its primary endpoint and cabozantinib provided a statistically significant and clinically meaningful improvement versus placebo in overall survival (OS). The median OS was 10.2 months with Cabometyx compared with 8.0 months with placebo. The Median progression-free survival (PFS) more than doubled, at 5.2 months with Cabometyx compared with 1.9 months with placebo. The trial showed that disease control (partial response or stable disease) was achieved by 64% of the Cabometyx group compared with 33% of the placebo group. The companies plan to present the results at a symposium in San Francisco later this week.
We remind investors that Cabometyx is already approved in the United States for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. In December 2017, the FDA approved label expansion of Cabometyx for the treatment of previously untreated RCC. The approval came on the back of positive results from the randomized phase II, trial CABOSUN on first-line kidney cancer. The results demonstrated statistically significant and clinically meaningful improvement in PFS versus Pfizer Inc.’s (PFE - Free Report) Sutent.
Exelixis’ share price has increased 64.5% over a year compared with the industry’s gain of 2.6%.
HCC is the most common form of liver cancer, accounting for more than 90% of cases in the United States. Hence there is a dire need to bring new treatment options. Exelixis plans to submit a supplemental new drug application to the FDA in the first quarter of 2018.
Cabometyx raked in strong sales in the first nine months of 2017, courtesy of the increasing demand for the drug. A potential approval will further boost the sales of the drug. .
Exelixis has also initiated a phase Ib study (investigator-sponsored) on Cabometyx (in combination with Bristol-Myers Squibb Company’s (BMY - Free Report) Opdivo (nivolumab) or Opdivo plus Yervoy) in patients suffering from genitourinary tumors, including bladder cancer and RCC.
Exelixis has also inked agreements with Bristol-Myers Squibb and Roche Holding AG (RHHBY - Free Report) to develop cabozantinib in combination with immunotherapy agents.
Exelixis, Inc. Price
Exelixis, Inc. Price | Exelixis, Inc. Quote
Zacks Rank
Exelixis sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>